Cochlear FY profit drops 22% but exceeds forecasts

Cochlear reported full-year underlying net profit of A$322.4M ($213M), down 22% YoY but ahead of Reuters expectations of A$303.9M, as softer demand and currency headwinds were partly offset by cost cuts. Revenue slipped 1% to A$2.34B (up 2% in constant currency), while statutory profit fell 62% to A$147.3M due to a A$109.1M non-cash Epiminder writedown and A$66M cloud spending. The company plans fixed-cost reductions to fund ~A$25M of growth spending, raises R&D 15%, forecasts low-single-digit constant-currency revenue growth with underlying profit of A$330M–A$350M for FY2027, and cuts the final dividend 40% to A$1.30/share (full-year dividends down 20% to A$3.45/share).

Analysis

The key market signal is not the earnings beat; it is the decision to defend growth through higher reinvestment while returning less cash. That usually reads as a near-term negative for a premium healthcare multiple because investors lose the dividend support and now have to underwrite execution on referral conversion and R&D payback instead of simply paying up for quality cash generation.

Competitive dynamics favor the broader hearing-care platforms over the pure implant incumbent in the next 1-3 months. If adult implantation remains sluggish, distributors and referral intermediaries will direct more volume toward vendors with a wider commercial footprint and better cross-sell into hearing aids; that incremental share pressure is harder to see in reported numbers but shows up later in mix and pricing. The most exposed holders are income-oriented accounts, which can create a technical overhang after the dividend reset.

The contrarian case is that this is a balance-sheet and operating leverage reset, not a collapse in demand. If cost discipline offsets growth spend and the referral campaign lifts adult conversion, the stock could re-rate over 6-18 months because the market is currently paying for stability, not reinvestment. What would falsify the bearish read is any evidence that the revenue guide is too conservative, especially if constant-currency growth accelerates for two consecutive quarters or if margin expansion resumes despite heavier R&D and cloud spending.

Key Decisions for Investors

• Do not chase CHEOY on the print; use any 2-4% post-earnings bounce to reduce exposure or underweight for the next 1-3 months. The thesis breaks if management raises constant-currency growth above low-single digits or shows two straight quarters of adult implant acceleration.
• Relative value: long SONVY vs. short CHEOY over 1-3 months to express share-shift risk from a narrower commercial footprint to a broader hearing-care platform. Target 5-8% relative underperformance for CHEOY if referral conversion stays slow.
• Watch-only long setup in CHEOY on a 10-15% pullback for 6-18 months, but only if the company proves the fixed-cost reset is real and incremental growth spend generates operating leverage. Risk/reward improves if margins stabilize before the dividend reset is fully digested.
• Set an alert on the next quarterly print for adult-implant volume and FX impact; if constant-currency growth does not re-accelerate, expect multiple compression as the market prices the stock more like a reinvestment story than a cash-return story.